Literature DB >> 22238307

Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences.

John Misasi1, Kartik Chandran, Jin-Yi Yang, Bryden Considine, Claire Marie Filone, Marceline Côté, Nancy Sullivan, Giulia Fabozzi, Lisa Hensley, James Cunningham.   

Abstract

Filoviruses are enveloped viruses that cause sporadic outbreaks of severe hemorrhagic fever [CDC, MMWR Morb. Mortal. Wkly. Rep. 50:73-77, 2001; Colebunders and Borchert, J. Infect. 40:16-20, 2000; Colebunders et al., J. Infect. Dis. 196(Suppl. 2):S148-S153, 2007; Geisbert and Jahrling, Nat. Med. 10:S110-S121, 2004]. Previous studies revealed that endosomal cysteine proteases are host factors for ebolavirus Zaire (Chandran et al., Science 308:1643-1645, 2005; Schornberg et al., J. Virol. 80:4174-4178, 2006). In this report, we show that infection mediated by glycoproteins from other phylogenetically diverse filoviruses are also dependent on these proteases and provide additional evidence indicating that they cleave GP1 and expose the binding domain for the critical host factor Niemann-Pick C1. Using selective inhibitors and knockout-derived cell lines, we show that the ebolaviruses Zaire and Cote d'Ivoire are strongly dependent on cathepsin B, while the ebolaviruses Sudan and Reston and Marburg virus are not. Taking advantage of previous studies of cathepsin B inhibitor-resistant viruses (Wong et al., J. Virol. 84:163-175, 2010), we found that virus-specific differences in the requirement for cathepsin B are correlated with sequence polymorphisms at residues 47 in GP1 and 584 in GP2. We applied these findings to the analysis of additional ebolavirus isolates and correctly predicted that the newly identified ebolavirus species Bundibugyo, containing D47 and I584, is cathepsin B dependent and that ebolavirus Zaire-1995, the single known isolate of ebolavirus Zaire that lacks D47, is not. We also obtained evidence for virus-specific differences in the role of cathepsin L, including cooperation with cathepsin B. These studies strongly suggest that the use of endosomal cysteine proteases as host factors for entry is a general property of members of the family Filoviridae.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238307      PMCID: PMC3302294          DOI: 10.1128/JVI.06346-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry.

Authors:  Derek Dube; Kathryn L Schornberg; Charles J Shoemaker; Sue E Delos; Tzanko S Stantchev; Kathleen A Clouse; Christopher C Broder; Judith M White
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-03       Impact factor: 11.205

Review 2.  Exotic emerging viral diseases: progress and challenges.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

3.  Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.

Authors:  Jens H Kuhn; Sheli R Radoshitzky; Alexander C Guth; Kelly L Warfield; Wenhui Li; Martin J Vincent; Jonathan S Towner; Stuart T Nichol; Sina Bavari; Hyeryun Choe; M Javad Aman; Michael Farzan
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

4.  A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry.

Authors:  Anthony C Wong; Rohini G Sandesara; Nirupama Mulherkar; Sean P Whelan; Kartik Chandran
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

5.  Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change.

Authors:  Matthew Brecher; Kathryn L Schornberg; Sue E Delos; Marnie L Fusco; Erica Ollmann Saphire; Judith M White
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

6.  The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR.

Authors:  Andrea Marzi; Armin Akhavan; Graham Simmons; Thomas Gramberg; Heike Hofmann; Paul Bates; Vishwanath R Lingappa; Stefan Pöhlmann
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

8.  Rapid detection protocol for filoviruses.

Authors:  Manfred Weidmann; Elke Mühlberger; Frank T Hufert
Journal:  J Clin Virol       Date:  2004-05       Impact factor: 3.168

Review 9.  Lysosomal cysteine proteases (cathepsins): promising drug targets.

Authors:  Dusan Turk; Gregor Guncar
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2003-01-23

10.  Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.

Authors:  George Lin; Graham Simmons; Stefan Pöhlmann; Frédéric Baribaud; Houping Ni; George J Leslie; Beth S Haggarty; Paul Bates; Drew Weissman; James A Hoxie; Robert W Doms
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  66 in total

1.  Structural basis for Marburg virus neutralization by a cross-reactive human antibody.

Authors:  Takao Hashiguchi; Marnie L Fusco; Zachary A Bornholdt; Jeffrey E Lee; Andrew I Flyak; Rei Matsuoka; Daisuke Kohda; Yusuke Yanagi; Michal Hammel; James E Crowe; Erica Ollmann Saphire
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

2.  Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.

Authors:  Philipp A Ilinykh; Kai Huang; Rodrigo I Santos; Pavlo Gilchuk; Bronwyn M Gunn; Marcus M Karim; Jenny Liang; Mallorie E Fouch; Edgar Davidson; Diptiben V Parekh; James B Kimble; Colette A Pietzsch; Michelle Meyer; Natalia A Kuzmina; Larry Zeitlin; Erica Ollmann Saphire; Galit Alter; James E Crowe; Alexander Bukreyev
Journal:  Cell Host Microbe       Date:  2020-04-21       Impact factor: 21.023

3.  Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Authors:  John Misasi; Morgan S A Gilman; Masaru Kanekiyo; Miao Gui; Alberto Cagigi; Sabue Mulangu; Davide Corti; Julie E Ledgerwood; Antonio Lanzavecchia; James Cunningham; Jean Jacques Muyembe-Tamfun; Ulrich Baxa; Barney S Graham; Ye Xiang; Nancy J Sullivan; Jason S McLellan
Journal:  Science       Date:  2016-02-25       Impact factor: 47.728

4.  Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors.

Authors:  Manu Anantpadma; Jennifer Kouznetsova; Hang Wang; Ruili Huang; Andrey Kolokoltsov; Rajarshi Guha; Aaron R Lindstrom; Olena Shtanko; Anton Simeonov; David J Maloney; Wendy Maury; Douglas J LaCount; Ajit Jadhav; Robert A Davey
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Probing the virus host interaction in high containment: an approach using pooled short hairpin RNA.

Authors:  Claire Marie Filone; Ken Dower; Glenn S Cowley; Lisa E Hensley; John H Connor
Journal:  Assay Drug Dev Technol       Date:  2015-02-03       Impact factor: 1.738

6.  Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.

Authors:  Anna Z Wec; Andrew S Herbert; Charles D Murin; Elisabeth K Nyakatura; Dafna M Abelson; J Maximilian Fels; Shihua He; Rebekah M James; Marc-Antoine de La Vega; Wenjun Zhu; Russell R Bakken; Eileen Goodwin; Hannah L Turner; Rohit K Jangra; Larry Zeitlin; Xiangguo Qiu; Jonathan R Lai; Laura M Walker; Andrew B Ward; John M Dye; Kartik Chandran; Zachary A Bornholdt
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

7.  Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Authors:  Mallory Willet; Drishya Kurup; Amy Papaneri; Christoph Wirblich; Jay W Hooper; Steve A Kwilas; Rohan Keshwara; Andrew Hudacek; Stefanie Beilfuss; Grit Rudolph; Elke Pommerening; Adriaan Vos; Andreas Neubert; Peter Jahrling; Joseph E Blaney; Reed F Johnson; Matthias J Schnell
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

8.  Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry.

Authors:  Kazuya Shirato; Kazuhiko Kanou; Miyuki Kawase; Shutoku Matsuyama
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

9.  In search of cathepsins: how reovirus enters host cells.

Authors:  Bernardo A Mainou; Terence S Dermody
Journal:  DNA Cell Biol       Date:  2012-11-07       Impact factor: 3.311

Review 10.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.